Corporate Venture Capital’s Role In Developing Next-Generation Biologics: An Interview With Takeda Research Investment’s Graeme Martin (part 2 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
With private-equity investments in early-stage financing gone, corporate venture needs to support these opportunities, “because if you don’t, the biotechnology industry is going to disappear. It’s just going to dry up,” Martin maintains.